- Home
- APLT vs BELFB Comparison
APLT vs BELFB Comparison
Compare APLT & BELFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- BELFB
- Stock Information
- Founded
- APLT 2016
- BELFB 1949
- Country
- APLT United States
- BELFB United States
- Employees
- APLT N/A
- BELFB N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- BELFB
- Sector
- APLT Health Care
- BELFB
- Exchange
- APLT Nasdaq
- BELFB Nasdaq
- Market Cap
- APLT 128.0M
- BELFB 1.0B
- IPO Year
- APLT 2019
- BELFB N/A
- Fundamental
- Price
- APLT $0.90
- BELFB $81.03
- Analyst Decision
- APLT Buy
- BELFB Strong Buy
- Analyst Count
- APLT 7
- BELFB 3
- Target Price
- APLT $6.10
- BELFB $98.33
- AVG Volume (30 Days)
- APLT 8.4M
- BELFB 63.9K
- Earning Date
- APLT 11-07-2024
- BELFB 02-19-2025
- Dividend Yield
- APLT N/A
- BELFB 0.35%
- EPS Growth
- APLT N/A
- BELFB N/A
- EPS
- APLT N/A
- BELFB 4.32
- Revenue
- APLT N/A
- BELFB $524,943,000.00
- Revenue This Year
- APLT N/A
- BELFB N/A
- Revenue Next Year
- APLT $2,664.24
- BELFB $0.77
- P/E Ratio
- APLT N/A
- BELFB $18.74
- Revenue Growth
- APLT N/A
- BELFB N/A
- 52 Week Low
- APLT $0.77
- BELFB $45.75
- 52 Week High
- APLT $10.62
- BELFB $92.61
- Technical
- Relative Strength Index (RSI)
- APLT 19.46
- BELFB 45.93
- Support Level
- APLT $0.78
- BELFB $79.04
- Resistance Level
- APLT $0.90
- BELFB $83.98
- Average True Range (ATR)
- APLT 0.12
- BELFB 3.61
- MACD
- APLT 0.26
- BELFB -0.64
- Stochastic Oscillator
- APLT 20.97
- BELFB 18.45
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.